Literature DB >> 22970726

Orthopaedic co-morbidities in the elderly haemophilia population: a review.

D Stephensen1, E C Rodriguez-Merchan.   

Abstract

Due to improvements in the treatment and medical care of haemophilia, the life expectancy of individuals with haemophilia has approached that of the general population. To review the main co-morbidities of the musculoskeletal system in elderly persons with haemophilia, we have performed a review of the literature on the musculoskeletal problems of elderly haemophiliacs. Chronic arthropathy is the main co-morbidity in the ageing person with haemophilia. Age-related orthopaedic co-morbidities include degenerative joint changes, osteoporosis, muscle atrophy or sarcopenia, muscle weakness and disturbance of gait and balance. Increased pain, muscle weakness and atrophy along with an increased risk of falling are key features of advanced haemophilic arthropathy and ageing. An ageing haemophilia population in which arthropathy continues to be the primary co-morbidity is a current challenge for those responsible for their care. Exercise programmes undertaken two to three times per week for at least 12 weeks seem most effective in reducing the impact of age-related changes on the musculoskeletal system. Establishing effective exercise programmes and strategies to identify individuals who would benefit from early surgical intervention together with presurgical physiotherapy prehabilitation is a priority for future research.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22970726     DOI: 10.1111/hae.12006

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice.

Authors:  Jhansi Magisetty; Vijay Kondreddy; Shiva Keshava; Kaushik Das; Charles T Esmon; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Blood       Date:  2022-05-05       Impact factor: 25.476

2.  EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; Charles T Esmon; L Vijaya Mohan Rao
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

3.  Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway.

Authors:  Coline Haxaire; Narine Hakobyan; Tania Pannellini; Camila Carballo; David McIlwain; Tak W Mak; Scott Rodeo; Suchitra Acharya; Daniel Li; Jackie Szymonifka; Xiangqian Song; Sébastien Monette; Alok Srivastava; Jane E Salmon; Carl P Blobel
Journal:  Blood       Date:  2018-05-18       Impact factor: 22.113

4.  Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project.

Authors:  Chiara Biasoli; Erminia Baldacci; Antonio Coppola; Raimondo De Cristofaro; Matteo N D Di Minno; Giuseppe Lassandro; Silvia Linari; Maria E Mancuso; Mariasanta Napolitano; Gianluigi Pasta; Angiola Rocino
Journal:  Blood Transfus       Date:  2021-10-15       Impact factor: 3.443

5.  Manual therapy in the treatment of patients with hemophilia B and inhibitor.

Authors:  Rubén Cuesta-Barriuso; Roberto O Trelles-Martínez
Journal:  BMC Musculoskelet Disord       Date:  2018-01-22       Impact factor: 2.362

6.  An e-Prehabilitation System of Care for Teenagers and Young Adults Diagnosed With Cancer: Protocol for a Qualitative Co-Design Study.

Authors:  Lisa McCann; Kathryn A McMillan; Christopher Hewitt
Journal:  JMIR Res Protoc       Date:  2018-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.